BD PhaSeal™ System Receives Clearance from FDA Under Newly Created ONB Product Code

BD PhaSeal™ System Receives Clearance from FDA Under Newly Created ONB Product
                                     Code

First and Only FDA Cleared Closed System Transfer Device Indicated to Reduce
Exposure to Hazardous Drugs

PR Newswire

FRANKLIN LAKES, N.J., Jan. 15, 2013

FRANKLIN LAKES, N.J., Jan. 15, 2013 /PRNewswire/ -- BD Medical, a segment of
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical
technology company, today announced that the U.S. Food and Drug Administration
(FDA) has cleared the BD PhaSeal™ Closed System Transfer Device (CSTD) under
the newly created ONB code. The BD PhaSeal System is the first and only
cleared CSTD under the new code, which was created for devices that have
specific indications for use with antineoplastic and other hazardous drugs.

The FDA clearance was based on three criteria: no escape of hazardous drug or
vapor concentration, no transfer of environmental contaminants, and prevention
of microbial ingress.The BD PhaSeal System is the only CSTD currently
available that meets all three of these standards.

"Given BD's commitment to creating a safe working environment for healthcare
workers, we're pleased at the FDA's clearance of the BD PhaSeal System under
the new ONB code. It reinforces our ability to protect healthcare workers from
exposure to hazardous drugs," said William A. Tozzi, President, BD Medical –
Medical Surgical Systems. "The BD PhaSeal System exemplifies our goal of
enabling healthcare facilities to reduce workplace hazards and exceed
compliance standards while providing quality patient care."

The FDA created the new ONB code because it recognized that a new product code
would be in the best interest of public health and wanted to improve the
information available to users of devices that have specific indications for
use with antineoplastic and other hazardous drugs. The BD PhaSeal System
obtained ONB clearance through validated third-party evidence. Please visit
www.bd.com/PhaSeal for more information.

About the BD PhaSeal™ System
The BD PhaSeal™ System is a closed system transfer device (CSTD) that reduces
healthcare workers' exposure to hazardous, parenteral medications from
preparation in the pharmacy to administration with the patient. The BD PhaSeal
System is an airtight and leak-proof CSTD that mechanically prohibits the
transfer of environmental contaminants into the system and the escape of drug
or vapor concentrations outside the system, thereby minimizing individual and
environmental exposure to drug vapor aerosols and spills. The BD PhaSeal
System also prevents microbial ingress. With a limited number of components
and only one connection interface, the BD PhaSeal System dimensions are
created to ISO standards to be compatible with all standard size drug vials
and tubing.

About BD
BD is a leading global medical technology company that develops, manufactures
and sells medical devices, instrument systems and reagents. The Company is
dedicated to improving people's health throughout the world. BD is focused on
improving drug delivery, enhancing the quality and speed of diagnosing
infectious diseases and cancers, and advancing research, discovery and
production of new drugs and vaccines. BD's capabilities are instrumental in
combating many of the world's most pressing diseases. Founded in 1897 and
headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000
associates in more than 50 countries throughout the world. The Company serves
healthcare institutions, life science researchers, clinical laboratories, the
pharmaceutical industry and the general public. For more information, please
visit www.bd.com.

Contact:
Abigail Cardona
BD Public Relations
201-847-4605
abigail_cardona@bd.com

SOURCE BD-Becton Dickinson

Website: http://www.bd.com
 
Press spacebar to pause and continue. Press esc to stop.